Business
BioGene Therapeutics Inc. Appoints Dr. Francis Tavares, PhD., as Chief Technology Officer
Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed of Dr. Francis Tavares as Chief Technology Officer effective on 19 August, 2025.Dr. Francis
About this update from Preveceutical Medical Inc
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed of Dr. Francis Tavares as Chief Technology Officer effective on 19 August, 2025.","length":508,"tagName":"p"},{"type":"text","content":"Dr. Francis Tavares leads the biopharmaceutical industry, most recently serving as President, CEO, and Founder of ChemoGenics BioPharma, where he spearheaded drug discovery initiatives. He has built state-of-the-art facilities and fostered collaborations that supported multiple Phase I and II SBIR grants, while also securing venture capital investment for commercialization. He also served as Group Manager in the Medicinal Chemistry Division at GlaxoSmithKline (GSK), where he earned the Excellence in Science Award in 2004.","length":527,"tagName":"p"},{"type":"text","content":"Dr. Tavares holds a PhD in Organic Chemistry from Colorado State University and completed postdoctoral research at the University of Texas at Austin, which he has utilized to lead the development of small-molecule inhibitors for kinases, proteases, and nuclear receptors. These have resulted in significant milestones, including the commercialization of Trilaciclib and the successful completion of Phase 3 clinical trials of Lerociclib, the best-in-class CDK4/6 inhibitor. With a robust track record of championing over 15 metabolic targets and leading multidisciplinary teams in medicinal chemistry, pharmacokinetics, and toxicology, Dr. Tavares has consistently delivered candidates for clinical trials.","length":706,"tagName":"p"},{"type":"text","content":""We are thrilled to welcome Dr. Tavares to the executive team of BioGene Therapeutics," said Stephen Van Deventer, Chairman & CEO of BioGene Therapeutics Inc. "His thirty years of experience in drug discovery, organic and medical chemistry, paired with his proven track record of turning scientific innovation into successful products, will make him an invaluable part of our company's team. We believe his insights will be crucial to exp...